Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02064829
First received: February 14, 2014
Last updated: February 10, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)